The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A Study in Healthy Volunteers to Assess the Tolerability and Blood Levels of a Single Dose of AZD7687
- collapse A randomised, single-blind, placebo-controlled, two-centre phase I study in healthy volunteers to assess the safety, tolerability and pharmacokinetics of AZD8329 after single ascending oral doses
- collapse A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral AZD8329 after Administration of Multiple Ascending Doses in Abdominally Obese but otherwise Healthy Male Subjects
- collapse A sequential, open label study to compare the pharmacokinetics,safety and tolerability of Ticagrelor and Venlafaxine given concomitantly in healthy subjects aged 18 to 45 years.
- collapse PATTERN OF STATINS USE IN CATALONIA
- collapse Bioequivalence Study of the Fixed-dose Combination of Saxagliptin/Metformin XR Tablets Relative to Saxagliptin (Onglyza™ ) Tablets and Australia-sourced Diabex XR Tablets Coadministered to Healthy Subjects in the Fed State During Steady-state Administration
- collapse A 24-week, multicentre, randomised, double-blind,age-stratified, placebo controlled phase III study with an 80-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg /day in patients with T2DM and cardiovascular disease, who exhibit inadequate glycaemic control on usual care
- collapse A 24-week, multicentre, randomised, double-blind, age-stratified, placebo controlled, phase III study with a 80-week extension period to evaluate the efficacy and safety of dapagliflozin 10 mg/day in pts with T2DM, CV disease and hypertension who exhibit inadequate glycaemic control on usual care
- collapse A 24-week,Multicentre,Randomised,Double-Blind,Placebo-Contr,Parallel-Group,International Phase III Study with 24week Extension to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg/Day in patients with Type 2 Diabetes who have Inadequate Glyc Control on a DPP-4 inhibitor Sitagliptin+/-Metformin
- collapse A 24-week international, randomized, parallel-group, double-blind, placebo-controlled Phase III study with a 24-week extension period to evaluate the efficacy and safety of dapagliflozin therapy when added to the therapy of patients with type 2 diabetes with inadequate glycaemic control on insulin
